An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty

Hospital for Special Surgery (HSS)

Status: Terminated

Conditions: Orthostatic Hypotension

Treatments: Other: Intravenous fluid bolus; Drug: Midodrine

Study type: Interventional

Funder types: Other

Identifiers

NCT02154243

2013-114

Details and patient eligibility

About

Orthostatic hypotension following total hip arthroplasty is known to limit the ability of patients to perform physical therapy (PT) and increase the length of hospital stay and costs. Our goal is to prospectively study the effects of oral midodrine on the signs and symptoms of orthostatic hypotension in 20 patients and the effects of intravenous fluid on the signs of symptoms of orthostatic hypotension in 10 patients. Midodrine will be administered to patients with suspected low SVV, and an intravenous fluid bolus will be administered to patients with low CO. 120 patients will be consented with a view to studying 30 patients who meet the inclusion criteria for orthostatic hypotension. Patients who receive midodrine or the fluid bolus will undergo hemodynamic measurements at 30 min, 1 hr, 2 hrs, 3 hrs, and 4 hrs post-intervention. All patients will undergo measurements for blood pressure, arterial augmentation index, and heart rate at baseline (pre-op; holding area) and the time of first PT attempt. Patients will be monitored up to post-operative day 3. The working hypothesis is that midodrine or fluid therapy will significantly raise the mean arterial blood pressure (MAP) by 5 mmHg+ and/or cause a significant change in the Orthostatic Hypotension Questionnaire (characterized by a two-point improvement in symptom score).

Enrollment: 13 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of participating surgeons undergoing unilateral primary total hip arthroplasty
• Ages 18-90
• English-speaking
• If the patients are diagnosed with orthostatic hypotension (fall in SBP of at least 20 mmHg or DBP of at least 10 mmHg within 3 min of assuming a sitting/standing position)

Exclusion criteria

• Body mass index > 40
• Low ejection fraction (<50%)
• Clinical diagnosis of congestive heart failure
• Aortic insufficiency characterized as greater than moderate
• Severe uncontrolled hypertension
• Symptomatic bradycardia (HR < 50 bpm and symptoms)
• Creatinine > 1.2 mg/dl
• Hepatic insufficiency
• Severe respiratory disease in which supplemental oxygen is required
• History of severe urinary retention
• Use of MAO inhibitors
• Severe supine hypertension (SBP >= 150 mmHg or DBP >= 90 mmHg)
• History of visual problems and using fludrocortisone acetate
• Contraindication for repeated BP measurements
• Revision THA and additional procedures
• Clonidine use

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

13 participants in 3 patient groups

Midodrine

Experimental group

Description:

Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV\<15 will be given oral midodrine, 10 mg, once.

Treatment:

Drug: Midodrine

Intravenous fluid bolus

Experimental group

Description:

Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV\>=15 will be given intravenous fluid bolus, 15 cc/kg, once.

Treatment:

Other: Intravenous fluid bolus

Control (no intervention)

No Intervention group

Description:

Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.